scPharmaceuticals Inc. (NASDAQ:SCPH) Stake Lifted by Walleye Capital LLC

Walleye Capital LLC increased its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 27.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 475,555 shares of the company’s stock after purchasing an additional 101,148 shares during the period. Walleye Capital LLC’s holdings in scPharmaceuticals were worth $2,169,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SCPH. Suvretta Capital Management LLC acquired a new position in shares of scPharmaceuticals during the 3rd quarter valued at $9,343,000. Rubric Capital Management LP grew its holdings in scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after acquiring an additional 1,250,000 shares during the period. King Luther Capital Management Corp raised its position in scPharmaceuticals by 51.8% in the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after acquiring an additional 752,005 shares in the last quarter. Stonepine Capital Management LLC lifted its holdings in scPharmaceuticals by 84.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock valued at $3,552,000 after acquiring an additional 357,171 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in shares of scPharmaceuticals during the 2nd quarter valued at about $1,544,000. 89.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on SCPH. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a report on Thursday, November 14th. Craig Hallum dropped their price target on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

scPharmaceuticals Trading Down 3.0 %

NASDAQ:SCPH opened at $3.60 on Wednesday. The stock has a fifty day simple moving average of $4.06 and a 200 day simple moving average of $4.39. The firm has a market capitalization of $180.14 million, a price-to-earnings ratio of -1.89 and a beta of 0.14. scPharmaceuticals Inc. has a 1-year low of $3.08 and a 1-year high of $6.71. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.